Automated Insulin Delivery Technology in the Hospital: Update on Safety and Efficacy Data
Authors' conclusion
The type of CSII technology encountered in the hospital is shifting from non-AID toward AID technologies. This analysis supports earlier findings that outpatient AID systems can be successfully transitioned into the inpatient setting. Further study is needed to define if AID systems offer any advantage in glycemic control.
Study context
- Population
- Inpatients using automated insulin delivery (AID) technology or other continuous subcutaneous insulin infusion (CSII) on admission to one hospital, June 2020–December 2022analysed
- Participants
- 185 inpatients
- Exposure
- AID vs non-AID CSII vs CSII discontinued in hospital
- AIDn = 64
- Non-AIDn = 86reference
- CSII discontinuedn = 35
- Outcome
- Inpatient glycemic control
- Follow-up
- Patient stay
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Patient-stay mean glucose and % hypoglycemic events similar between all groups (pairwise comparisons)
- % hyperglycemic measurements significantly lower in the AID cohort
Observational data: associations, not effects.
Further findings
Trend in CSII technology use · June 2020–December 2022
- Number of patients on AID increased over the period, while non-AID users decreased
Safety
- No adverse events (DKA, pump site complications, equipment malfunction) reported in either CSII cohort
Original publication
Automated Insulin Delivery Technology in the Hospital: Update on Safety and Efficacy Data. Endocr Pract. Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →